

ASX Announcement 20 February 2017

Boardroom Media Interview: Strong Half Year Results and ITL BioMedical Update

ITL Limited is pleased to provide the opportunity to listen to an audio interview with Mr Bill Mobbs, Executive Chairman.

Mr Mobbs talks about the Company's strong first half results that saw revenue rise 11%, EBITDA up 69% and profit before tax grow 110% versus the previous comparative period, and provides an insight into ITL's innovative products range and the exciting growth opportunities in the BioMedical division.

Click here for the Boardroom Media interview:

https://boardroom.media/broadcast/?refid=&eid=58a656ae196ffa2970ec87c9

ITL Limited ABN 16 088 212 088 Unit 1, 63 Wells Road Chelsea Heights, Victoria, 3196

ITL is an innovative diversified medical technology company that creates and manufactures leading edge medical devices for Operating Theatres, Bloodbanks and laboratories.

ITL's patented medical devices are sold in over 50 countries and protect healthcare workers in millions of procedures annually.

ITL's wholly owned subsidiary MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16th most Innovative Company by the AFR Innovative Companies Awards

Australian Securities Exchange

Code: ITD

Ordinary Shares

95,928,314

Board of Directors

Bill Mobbs Executive Chairman
Mark Peatey Non-executive Director
Andrew Turnbull Non-executive Director

Trevor Doolan Chief Financial Officer

ITL Contact

Trevor Doolan Company Secretary
Phone: +61 3 8773 3050
Email: info@itl-limited.com

www.itl-limited.com

Media

Ben Knowles Walbrook IR
Phone: +61 426 277 760
Email: ben.knowles@walbrookir.com.au